Subject: FDA Approves Xenazine for Chorea in Huntington’s Disease
Date: 8/20/2008The United States Food and Drug Administration has approved tetrabenazine (Xenazine®) for symptomatic reduction of chorea in Huntington’s disease. It is the first drug approved for treatment of any symptom of HD. Tetrabenazine is already approved for use in Canada under the trade name Nitoman®. The drug is a dopamine depletor, and has been shown in a double-blind trial to reduce chorea severity in HD patients.
The FDA announcement can be found HERE.
|All contents copyright © WE MOVE 2013. This page last modified 5/23/2013.|